Xylometazoline is a direct-acting sympathomimetic amine, primarily an alpha-2 adrenergic receptor agonist, used as a topical nasal decongestant. It is a potent vasoconstrictor that acts on the alpha-adrenergic receptors in the arterioles of the nasal mucosa, leading to reduced blood flow, decreased edema, and relief of nasal congestion. It is a standard first-line therapy for symptomatic relief in allergic rhinitis, common cold, and sinusitis in the Indian clinical setting.
Adult: 0.1% solution/spray: 2-3 drops or 1-2 sprays into each nostril every 8 to 12 hours. Do not exceed 3 applications in 24 hours.
Note: 1. Blow nose gently to clear nostrils. 2. Tilt head slightly back. 3. Insert applicator tip just inside nostril, pointing away from the nasal septum. 4. Squeeze/spray while breathing in gently through the nose. 5. Avoid sniffing hard. 6. Do not share the bottle/dropper to prevent contamination. Use for a maximum of 5-7 consecutive days.
Xylometazoline is a potent, selective agonist of postsynaptic alpha-2 adrenergic receptors located on vascular smooth muscle cells within the nasal mucosa. Its activation leads to the constriction of capacitance vessels (venous sinusoids) and arterioles. This vasoconstriction reduces blood flow, decreases capillary permeability, and limits the production of nasal secretions, thereby shrinking the swollen nasal turbinates and relieving obstruction.
Pregnancy: Category C (US FDA). Animal studies show risk, human data inadequate. Use only if clearly needed and potential benefit justifies potential risk to the fetus. Short-term use at recommended doses is generally considered acceptable after physician consultation.
Driving: Unlikely to affect driving ability. However, if systemic effects like dizziness or blurred vision occur, avoid driving.
| Monoamine Oxidase Inhibitors (MAOIs) - e.g., Phenelzine, Tranylcypromine | Potentiates pressor effects, risk of severe hypertensive crisis. | Contraindicated |
| Tricyclic Antidepressants (TCAs) - e.g., Amitriptyline | May potentiate pressor effects of xylometazoline. | Major |
| Other Sympathomimetics (Oral/Parenteral) - e.g., Pseudoephedrine, Epinephrine | Additive sympathomimetic effects, increasing risk of hypertension, tachycardia. | Major |
| Beta-blockers (non-selective) - e.g., Propranolol | Unopposed alpha-adrenergic stimulation may lead to severe hypertension and bradycardia. | Moderate |
| Methyldopa | May enhance pressor response. | Moderate |
| Ergot Alkaloids - e.g., Ergotamine | Increased risk of severe vasoconstriction and ischemia. | Major |